Compare iShares Core High Dividend ETF (HDV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs ResMed Inc. — how do they compare? iShares Core High Dividend ETF trades at $28.72 (market cap $14.68B), while ResMed Inc. trades at $231 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.2× iShares Core High Dividend ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals.
| HDV | RMD | |
|---|---|---|
Market Cap | $14.68B | $31.89B |
Volume | 2,925,562 | 618,314 |
52-Week High | $29.93 | $277.88 |
52-Week Low | $23.64 | $182.82 |
Typical Hold Time | 117 Days | — |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.73, up 1.59% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the 3% yield may not fully compensate for increased concentration risk.
The outlook remains cautiously optimistic given the bullish technical setup and sector rotation benefits, but investors face risks from heightened concentration in three sectors (62% allocation) and potential yield compression. The ETF's performance relative to peers like VYM suggests competitive positioning, though sector concentration requires monitoring for diversification adequacy.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
